Oroxyloside A Overcomes Bone Marrow Microenvironment-Mediated Chronic Myelogenous Leukemia Resistance to Imatinib via Suppressing Hedgehog Pathway

Imatinib (IM), as first inhibitor of the oncogenic tyrosine kinase BCR-ABL, has been widely used to treat chronic myeloid leukemia (CML) for decades in clinic. However, resistance to IM usually occurs in CML patients. The bone marrow (BM), as the predominant microenvironment of CML, secretes an abun...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Front Pharmacol
Prif Awduron: Zhang, Xiaobo, Liu, Yicheng, Lu, Lu, Huang, Shaoliang, Ding, Youxiang, Zhang, Yi, Guo, Qinglong, Li, Zhiyu, Zhao, Li
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Frontiers Media S.A. 2017
Pynciau:
Pharmacology
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5554535/
https://ncbi.nlm.nih.gov/pubmed/28848440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00526
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg